Form 4: Clorox Director Christopher Williams Reports DSU Acquisition
Director Compensation Disclosure
Director Christopher J. Williams acquired 265.3672 deferred stock units in lieu of quarterly director fees.
Summary
- Director Christopher J. Williams acquired 265.3672 deferred stock units (DSUs) on March 31, 2026, in lieu of quarterly director fees.
- An additional 212.639 DSUs were acquired on February 13, 2026, through dividend reinvestment.
- The total beneficial ownership following these transactions is 22,074.5818 shares.
- DSUs are settled 1-for-1 in common stock upon the director's retirement or termination of service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.
Positives
- Director demonstrates alignment with long-term shareholder interests by opting for equity-based compensation.
- Increased total beneficial ownership to 22,074.5818 shares.
Negatives
- None identified.
Risks
- Value of deferred stock units is tied directly to the future performance of Clorox common stock.
Future Outlook
The filing does not provide forward-looking financial guidance for the company.
Management Comments
- The transactions reflect standard compensation practices under the Independent Directors' Deferred Compensation Plan.
Industry Context
StockSavvy.ai notes that director equity acquisitions via fee deferral are standard corporate governance practices intended to align board incentives with shareholder outcomes.
Comparison to Industry Standards
- The use of deferred stock units for director compensation is consistent with standard practices among S&P 500 consumer goods companies.
- The 1-for-1 settlement structure is a common industry benchmark for director equity plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Election | Director elected to receive deferred stock units in lieu of cash for quarterly fees. | 03/31/2026 | Neutral; aligns director compensation with equity performance. |
Stakeholder Impact
- Shareholders: Neutral impact as this represents standard director compensation.
Next Steps
- Settlement of deferred stock units upon the director's eventual retirement or termination of service.
Key Dates
| Date | Description |
|---|---|
| 02/13/2026 | Acquisition of DSUs via dividend reinvestment |
| 03/31/2026 | Acquisition of DSUs in lieu of director fees |
| 04/02/2026 | Filing date of the Form 4 |
Keywords
Clorox, CLX, Director, Insider Trading, Form 4, Deferred Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.